Loading...
Cart
0

Global Cholera Vaccine Market Expected to Reach $207 Million by 2025 - Allied Market Research

 
 

quote growth in the demand of cholera vaccines in low- & middle-income countries play a major role in the growth of the cholera vaccine market. Furthermore, rise in the prevalence of cholera diseases is expected to boost the market growth in the coming years. quote

Onkar Sumant
Manager, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, "Cholera Vaccine Market by Product and End User: Global Opportunity Analysis and Industry Forecast, 2018 - 2025," the global cholera vaccine market generated $65 million in 2017, and is projected to reach $207 million by 2025, growing at a CAGR of 15.6% from 2018 to 2025. The Dukoral segment accounted around half of the total market share in 2017.

Cholera is an acute, profusely watery diarrhea caused by Vibrio cholera and spreads through contamination of water and food. In addition, it is closely associated with poor sanitation and lack of clean drinking water. The number of global cholera disease cases accounts for around 35 million every year. Currently, the frequency of cholera epidemics has increased mainly in low- and middle-income countries. Cholera control is the main priority in cholera-endemic areas, which in turn increase the demand for the cholera vaccines.

The cholera vaccine market is expected to exhibit significant growth during the forecast period due to lack of proper sanitation & consumption of contaminated food and growth in awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players in the near future.

Based on end user, the market is categorized into hospitals & clinics, research & academic laboratories, and others. The hospitals & clinics segment presently dominates the market, and is expected to remain dominant during the forecast period. This is attributed to the fact that hospitals and clinics are authorized to organize campaigns for cholera vaccination, as the number of cases for cholera diseases is rapidly growing in LMICs.

Asia-Pacific was the leading revenue contributor to the global cholera vaccine market in 2017, and is expected to remain dominant throughout the forecast period due to increase in the prevalence of cholera disease and rise in importance of immunization. However, North America is expected to grow at the highest CAGR during the study period. This is attributed to the launch of the first and only oral cholera vaccine, Vaxchora, in the USA. Furthermore, the number of travelers to the cholera-affected countries is increasing, which in turn increases the demand for immunization.

The report provides a comprehensive analysis of the key players operating in the global cholera vaccine market industry, namely Valneva SE, Emergent BioSolutions, Inc. (PaxVax, Inc.), Astellas Pharma, Inc., Sanofi (Shantha Biotechnics Private Limited), Eubiologics Co., Ltd., and Johnson & Johnson (Crucell), Celldex Therapeutics, Inc. The other players in the in the cholera vaccine market industry include Merck & Co., Inc., GlaxoSmithKline plc., and others.

Key Findings Of The Study

  • Based on product, the Vaxchora segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 17.4% from 2018 to 2025.

  • Depending on end user, the pharmaceutical & biotechnology companies segment is expected to exhibit the highest CAGR during the forecast period.

  • U.S. generated the highest revenue in the global cholera vaccine market industry in 2017, accounting less than one-tenth of the global market in 2017.

  • North America is estimated to grow at a CAGR of 17.1% during the forecast period.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Abhinav Rautela
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
mediacommunications@alliedanalytics.com

 
 

First time buyer?
Check offers and discount on this report
To get this report

 
Click Here
 
 

quote Cholera Vaccine Market by Product (Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others) and End User (Hospitals & Clinics, Research & Academic Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025 quote

View Report
 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
 

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

 
Get Industry Data Alerts
 

Buy Full Version
"Global Cholera Vaccine Market"
Purchase Enquiry